Page 217 - Drug Class Review

Drug Effectiveness Review Project

donepezil placebo 97% 96% 10% 15% 14% 15% 4% 9% 5% 9% Post randomization exclusions: NR Overall loss to follow-up: 46 (22.2%) Loss to follow-up differential high: No placebo donepezil 26% 18% 18% 11% Page 139 of 205

ITT: Yes

NR Yes Yes Yes Fair

Final Report Update 1 Authors: Tariot et al. Year: 2001 ADVERSE EVENTS: Overall adverse effects reported: Diarrhea • Vomiting • Nausea • Anorexia • Significant differences in adverse events: ANALYSIS: ADEQUATE RANDOMIZATION: ADEQUATE ALLOCATION CONCEALMENT: BLINDING OF OUTCOME ASSESSORS: ATTRITION (overall): ATTRITION (treatment specific): Loss to follow-up: Withdrawals due to adverse events: QUALITY RATING: *primary outcome measures Alzheimer's Drugs